Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
Sponsor: Editas Medicine, Inc.
Summary
The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.
Key Details
Gender
All
Age Range
12 Years - 50 Years
Study Type
OBSERVATIONAL
Enrollment
54
Start Date
2024-06-17
Completion Date
2040-08
Last Updated
2025-04-02
Healthy Volunteers
No
Interventions
Safety and efficacy assessments
Assessed throughout the duration of the study.
Locations (18)
UCSF Benioff Children's Hospital
Oakland, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Smilow Cancer Hospital
New Haven, Connecticut, United States
Johns Hopkins All Children's Hospital
St. Petersburg, Florida, United States
Children's Healthcare of Atlanta
Atlanta, Georgia, United States
University of Minnesota
Minneapolis, Minnesota, United States
Columbia University Medical Center - Department of Pediatrics
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
Atrium Health
Charlotte, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Tristar Medical Group Children's Specialists/Sarah Cannon Center for Blood Cancers
Nashville, Tennessee, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Cook Children's
Fort Worth, Texas, United States
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Princess Margaret Cancer Centre-University Health Network
Toronto, Ontario, Canada